mRNA: Therapeutics and Global Markets
Report Scope:
This report is an analytical business tool with the primary purpose of providing a thorough evaluation of the global market for mRNA therapeutics for the prevention of infectious diseases (through prophylactic vaccines) and treatment of chronic (e.g., cancer, heart diseases) and several other rare diseases.
The report considers only “Western” or modern drugs and excludes any other type of drugs such as alternative therapies. This report covers technologies used for the development and delivery of mRNA therapeutics.
This study aims to analyze the dynamics and forecasts of the mRNA therapeutics market worldwide and provides key market propositions over a five-year forecast period. The report covers developed and emerging markets, and it provides -
- Detailed description, including demographics and cost burden, of various diseases including types of cancer (e.g., breast cancer and others), cardiovascular diseases (MI, IHD, etc.), infectious diseases (COVID-19, Zika, influenza, rabies, etc.), respiratory disorders, diabetes and rare disorders such as cystic fibrosis, OTC disorder, propionic acidemia, TTR amyloidosis and melanoma, among others.
- Detailed description and analysis of current mRNA therapeutics (mRNA vaccines, drugs and therapies).
- Market characterization, unmet need, and market size and segmentation (by region, segment, diseases).
- The current state of the market and the key markets for its future development.
- Major regional trends.
- Market drivers and restraints.
- Detailed market projections through 2026.
- Global competitive thrust in terms of competition and market shares.
- Key marketed and pipeline (research and development) products along with information about their regulatory status.
- Strategic landscape (mergers and acquisitions).
- Regulatory structure: new regulations that will influence the development of the mRNA therapeutics market.
- Pricing and reimbursement.
- Observations and conclusions on the future of mRNA therapeutics.
- Profiles of market participants and associations.
Report Includes:
- 32 data tables and 32 additional tables
- An overview of the global market for mRNA therapeutics
- Analyses of global market trends with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the major developments, pandemic threats, therapeutic developments, and technological developments of the mRNA therapeutics market
- Discussion on significant advantages of mRNA over protein or DNA-based delivery systems and description of demographic and economic trends, and outlook of the mRNA therapeutics market
- Evaluation of current market size and forecast and information on prophylactic vaccines, vaccine discovery and development, and R&D activities
- Analysis of the various innovative therapeutics as well as new promising vaccines intended for the prevention and treatment of various chronic and infectious diseases
- Assessment of regulatory structure, pricing and reimbursement scenario, and pipeline analysis of the new molecules & therapeutics
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Comprehensive company profiles of major players of the industry, including Amgen Inc., Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson and Novartis
- Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Intended Audience
- Methodology and Information Sources
- Geographic Breakdown
- Analyst's Credentials
- BCC Custom Research
- Related BCC Research Reports
- Chapter 2 Summary and Highlights
- Chapter 3 Target Diseases and Disorders
- Overview of Common Diseases and Disorders for mRNA Therapeutics
- Cancer
- Infectious Diseases
- Cardiovascular Disease
- Lifestyle Disorders
- Respiratory Disorders
- Musculoskeletal Disorders
- Gastrointestinal Disorders
- Urology Disorders
- Nephrology Disorders
- Immune Disorders
- Neurological Disorders
- Rare Diseases
- Other Disorders
- Tobacco Smoking and Associated Diseases
- Infectious Diseases: COVID-19 Pandemic Set the Stage for mRNA Therapeutics
- Chronic Diseases: Expanding Horizon for mRNA Therapeutics
- Rare Diseases: Large Unmet Need is Fueling mRNA Therapeutics
- Aging, Gender and Onset of Diseases
- Global Demographics
- U.S. Demographics
- European Demographics
- Japanese Demographics
- Current Challenges and Future Directions
- Chapter 4 RNA Therapeutics
- RNA Therapeutics Overview
- Evolution of RNA Therapeutics
- History of RNA Therapeutics
- Development of RNA Therapeutics and Types
- DNA vs. RNA Therapeutics
- Clinical Need for RNA Therapeutics
- Increasing Disease Population and Economic Burden
- Limitations of Traditional Therapeutics
- Therapeutic Limitations of Biologics
- Poor Management of Chronic Diseases
- Limited Treatment for Rare Diseases
- RNA Therapeutics
- Antisense Oligonucleotide (ASO) as Therapeutics
- Small Interfering RNA (siRNA) as Therapeutics
- miRNA as Therapeutics
- Aptamers as Therapeutics
- mRNA as Therapeutics
- Manufacturing RNA-Based Biopharmaceuticals
- Chromatographic Purification Steps
- Delivery of RNA Therapeutics
- Polymer Conjugation/Chemical Modification
- Encapsulation
- Lipid-Based Nanoparticles
- Polymer Nanomaterials
- Silica Nanoparticles
- Carbon and Gold Nanomaterials
- GalNAc
- Institution and Hospital-Based RNA Therapeutics
- Regulatory Influence on the Market for RNA Therapeutics
- Market Situation for RNA Therapeutics
- Well-Developed Markets
- Developing Markets
- Underdeveloped Markets
- Therapeutics and Cost Burden
- Unmet Need
- Current Challenges and Future Developments
- Chapter 5 mRNA Vaccines
- Vaccines: Overview
- Vaccine-Based Disease Prevention
- Evolution of mRNA as Vaccine
- Clinical Need for mRNA Vaccines
- mRNA Vaccines and Types by Application
- Prophylactic/Protective Vaccines
- Therapeutic Vaccines
- mRNA Vaccine Product Segments
- Non-amplifying mRNA Vaccines
- Self-amplifying mRNA Vaccines
- Immunogenicity and mRNA Vaccines
- Optimizing Injection Routes
- Co-encapsulation of Other Stimulatory Molecules
- Formulation and Delivery of mRNA Vaccine
- Approaches for Enhancing mRNA Stability
- Advantages of mRNA Vaccines
- Traditional Vaccine vs. mRNA Vaccines
- Marketed/Commercial mRNA Vaccines
- Moderna
- BioNTech
- mRNA Vaccine Pipeline and New Developments
- mRNA Vaccine Pipeline by Company
- mRNA Vaccines: New Developments
- mRNA Vaccines and Future Pandemics
- Unmet Need
- Current Challenges and Future Outlook
- Chapter 6 mRNA Drugs and Therapies
- Overview of Drugs and Therapeutics
- Therapeutic-Based Disease Treatment
- Evolution of mRNA: Beyond Vaccines
- Clinical Need for mRNA Therapeutics Beyond Vaccines
- mRNA Vaccines vs. mRNA Therapeutics
- mRNA Therapeutics and Types
- mRNA as Gene and Protein Replacement Therapy
- mRNA-Enhanced Cell Therapies
- mRNA-Enhanced Immunotherapies (Monoclonal Antibody)
- Advantages mRNA Drugs and Therapies
- Delivery of mRNA Therapeutics
- mRNA Therapeutics Pipeline and New Developments
- mRNA Drugs for Protein Therapy Targeting Metabolic and Rare Diseases
- Pipeline for mRNA-Therapeutics by Company
- Pipeline for mRNA-Enhanced Cell Therapies
- mRNA Therapeutics and New Developments
- Widespread Concerns over the mRNA Medicinal Industry
- Issues with Personalized Medicine
- Unmet Need for mRNA Therapeutics
- Current Challenges and Future Outlook
- Chapter 7 Market Size and Growth Analysis
- Overview
- Market Size and Growth Analysis by Region
- Market Size and Growth Analysis by Product Segment
- mRNA Vaccines vs. Traditional Vaccines
- mRNA Drugs and Therapies
- Market Size and Growth Analysis by Therapeutic Treatment Type
- Market Size and Growth Analysis by Disease Type
- Market Growth Drivers and Restraints
- Market Growth Drivers
- Market Restraints
- Regulatory Impact on the Market for mRNA Therapeutics
- SWOT Analysis of the Market for mRNA Therapeutics
- Chapter 8 Competitive Landscape in the Market for mRNA Therapeutics
- Disease Prevention and Treatment with mRNA Therapeutics
- Chapter 9 Strategies in the Market for mRNA Therapeutics
- Consolidation in the Pharmaceutical Market
- Mergers and Acquisitions in the Biopharmaceutical Market
- Recent Strategic Moves in mRNA Therapeutics
- Key M&A and In-licensing Deals
- Key Strategic Partnerships
- Key Venture Financing Deals
- Future Strategic Landscape
- Chapter 10 Regulatory Structure for Biopharmaceuticals
- Regulatory Background
- Regulatory Systems for Biopharmaceuticals by Region
- United States
- Europe
- Japan
- Regulatory Systems for Medical Devices by Region
- United States
- European Union
- Japan
- Regulations for mRNA Therapeutics
- Current Regulatory Issues for mRNA Therapeutics
- Moderna Vaccine Regulation in the U.K.
- Key Regulatory Updates, 2020
- Pharmaceuticals
- Medical Devices
- Chapter 11 Pricing and Reimbursement: Pharmaceuticals and Biologics
- Pricing and Reimbursement Background
- Pricing and Reimbursement of Pharmaceuticals and Biologics by Region
- United States
- Private Health Insurance
- Chronic Diseases and Cost Burden on Medicare
- Rise of Infectious Diseases and Pricing & Reimbursement for Vaccines in the US.
- Europe
- Japan
- Pricing and Reimbursement Challenges for Pharmaceuticals
- Patented Medicines Price
- Prices of Older Drugs
- Pricing and Reimbursement for Medical Devices by Region
- United States
- Europe
- Japan
- Other Parts of Asia-Pacific
- Chapter 12 Conclusions on the Outlook for mRNA Therapeutics
- Major Developments Influencing the Market
- Digital Transformation and Technological Developments
- Increasing R&D Spend and Shift Towards Modern Therapeutics and Technologies
- Collaborations for Advanced Therapeutics
- Market Consolidation for Strategic Growth and to Retain Market Leadership
- Demographic and Economic Trends
- Changing Structure of the Pharma and Healthcare Industry
- Lifestyle Medicine
- Patient-Centric Programs
- Prevalence of Self-Care
- Burden on Public Health System
- Long-Term Outlook
- Chapter 13 Company Profiles
- ACCURNA INC.
- AMGEN INC.
- ARCTURUS THERAPEUTICS INC.
- ARGOS THERAPEUTICS INC.
- ARROWHEAD PHARMACEUTICALS
- ATHERSYS
- BIOCAD
- BIONTECH
- BOEHRINGER INGELHEIM
- CANSINOBIO
- CARTESIAN THERAPEUTICS INC.
- CHIMERON BIO
- CRISPR THERAPEUTICS INC.
- CUREVAC
- DAIICHI SANKYO
- ELI LILLY AND CO.
- ELIXIRGEN THERAPEUTICS INC.
- ETHERNA IMMUNOTHERAPIES
- ETHRIS GMBH
- GENENTECH (SUBSIDIARY OF ROCHE)
- GLAXOSMITHKLINE PLC
- GREENLIGHT BIOSCIENCES INC.
- HDT BIO CORP.
- IN-CELL-ART
- INTELLIA THERAPEUTICS
- IONIS PHARMACEUTICALS INC.
- JOHNSON & JOHNSON
- KERNAL BIOLOGICS INC.
- MAXCYTE INC.
- MERCK KGAA
- MERCURNA
- MODERNA THERAPEUTICS
- NOVARTIS
- NUTCRACKER THERAPEUTICS
- PFIZER
- PHION THERAPEUTICS
- POSEIDA THERAPEUTICS INC.
- QUARK PHARMACEUTICALS
- RECODE THERAPEUTICS
- REGULUS THERAPEUTICS
- RNAIMMUNE INC.
- ROCHE
- SANGAMO THERAPEUTICS INC.
- SANOFI
- SAREPTA THERAPEUTICS
- SHANGHAI BENDAO GENE TECHNOLOGY CO., LTD.
- STEMIRNA THERAPEUTICS LTD.
- STRAND THERAPEUTICS
- TIBA BIOTECHNOLOGY LLC
- TRANSLATE BIO
- VERTEX PHARMACEUTICAL
- Chapter 14 Appendix A: List of Acronyms
- Chapter 15 Appendix B: Professional Organizations
- American Heart Association (AHA)
- The Bill and Melinda Gates Foundation (BMGF)
- Canada's International Development Research Centre (IDRC)
- Center for Devices and Radiological Health (CDRH)
- Center for Drug Evaluation and Research (CDER)
- Centers for Medicare and Medicaid Services (CMS)
- The Coalition for Epidemic Preparedness Innovations (CEPI)
- Hormone Foundation
- International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
- National Center for Biotechnology Information (NCBI)
- National Institute of Aging (NIA)
- Network for Excellence in Health Innovation (NEHI)
- Pharmaceuticals and Medical Devices Agency (PMDA)
- U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)
- U.S. Food and Drug Administration (FDA)
- U.S. National Institutes of Health (NIH)
- World Cancer Research Fund International
- World Health Organization (WHO)
- List of Tables
- Summary Table : Global Market for mRNA Therapeutics, by Country/Region, Through 2026
- Table 1 : Global Prevalence of Breast Cancer Cases, by Country/Region, Through 2025
- Table 2 : Global Epidemiology of Colorectal Cancer, by Region, Through 2030
- Table 3 : Global Cancer-Related Deaths, by Cancer Type, Through 2030
- Table 4 : Share of Global Cancer-Related Deaths, by Cancer Type, 2015
- Table 5 : Case Fatality Rate, Global Viral Outbreaks, 2020
- Table 6 : Global Incidence Share of Hypertension, by Patient Group Type, 2020
- Table 7 : Global Prevalence of Angina Pectoris and Stroke (Survivors), Through 2030
- Table 8 : Global Prevalence of Congestive Heart Failure and Stroke, Through 2030
- Table 9 : Structural Heart Disease Management Through Medication
- Table 10 : BMI Categories Based on Increasing Health Risks
- Table 11 : Trends in Obesity Composition of the Global Population, Through 2025
- Table 12 : Obesity and Severe Obesity vs. General Population in the U.S., Through 2025
- Table 13 : Global Share of Diabetes, by Type
- Table 14 : Global Prevalence of Diabetes, by Type, Through 2040
- Table 15 : Global Symptomatic Prevalence of Key Musculoskeletal Disorders, Through 2025
- Table 16 : Global Deaths, by Musculoskeletal Disorder, Through 2030
- Table 17 : Global Deaths from Digestive Diseases, by Region, Through 2025
- Table 18 : Global Mortality Share, by Chronic Disease Type, 2019
- Table 19 : Global Shares of DALYs, by Chronic Disease Type, 2019
- Table 20 : Estimated World Population and Annual Growth, by Age Group, Through 2030
- Table 21 : Total Global Population, by Select Country/Region, Through 2030
- Table 22 : U.S. Population Estimates and Projections, by Age Group, Through 2030
- Table 23 : Estimates of Anticipated U.S. Life Expectancy at Birth, by Gender, Through 2020
- Table 24 : European Population Estimates and Projections, by Age Group, Through 2030
- Table 25 : Japanese Population Estimates and Projections, by Age Group, Through 2030
- Table 26 : Traditional Vaccines vs. mRNA Vaccines
- Table 27 : Marketed/Commercial mRNA Vaccines, by Company
- Table 28 : Clinical Development of mRNA Vaccine, BioNTech
- Table 29 : Clinical Development of mRNA Vaccine, Moderna
- Table 30 : Clinical Development of mRNA Vaccine, CureVac
- Table 31 : Clinical Development of mRNA Vaccine, Translate Bio
- Table 32 : Clinical Development of mRNA Vaccine, Arcturus Therapeutics
- Table 33 : Clinical Development of mRNA Vaccine, eTheRNA
- Table 34 : mRNA Vaccine Development Pipeline, by Others
- Table 35 : Clinical Development of mRNA Vaccines, by Research Institution
- Table 36 : mRNA Drugs for Protein Therapy, Metabolic and Rare Diseases, by Company
- Table 37 : mRNA Therapeutics, Non-viral Delivery for mRNA-Based Protein Therapy and Gene Editing, by Company
- Table 38 : Clinical Development of mRNA Therapeutics, Moderna
- Table 39 : Clinical Development of mRNA Therapeutics, Translate Bio
- Table 40 : Clinical Development of mRNA Therapeutics, BioNTech
- Table 41 : Clinical Development of mRNA Therapeutics, CureVac
- Table 42 : Clinical Development of mRNA Therapeutics, Arcturus Therapeutics
- Table 43 : Clinical Development of mRNA Therapeutics, Argos Therapeutics
- Table 44 : Clinical Development of mRNA Therapeutics, Mercurna
- Table 45 : Clinical Development of mRNA Therapeutics, Kernal Biologics
- Table 46 : Clinical Development of mRNA Therapeutics, Shanghai Bendao Gene Technology
- Table 47 : Global Market for mRNA Therapeutics, by Country/Region, Through 2026
- Table 48 : Global Market for mRNA Therapeutics, by Product Segment, Through 2026
- Table 49 : Global Market Shares of COVID-19 Vaccines, by Type, 2021
- Table 50 : Global Market Shares of mRNA Vaccines vs. Traditional Vaccines, 2021
- Table 51 : Global Market Shares of mRNA Therapeutics, by Therapeutic Treatment Type, 2026
- Table 52 : Global Market for mRNA Therapeutics, by Disease Type, Through 2026
- Table 53 : SWOT Analysis of the Market for mRNA Therapeutics
- Table 54 : Global Market for mRNA Therapeutics, by Company, 2021
- Table 55 : Intellectual Property Landscape for mRNA Therapeutics, by Company, 2021
- Table 56 : Key Strategic M&A and In-Licensing Deals in the Market for mRNA Therapeutics, by Company, 2019 and 2020
- Table 57 : Key Strategic Partnerships in the Market for mRNA Therapeutics, by Company, 2019-2020
- Table 58 : Key Strategic Venture Financing Deals, mRNA Therapeutics, by Company, 2020
- Table 59 : Countries that Authorized Moderna’s Vaccine for COVID-19
- Table 60 : Standard Vaccine Pricing Process in the U.S.
- Table 61 : COVID-19 Vaccine Price Range in the U.S., by Federal Government Purchase
- Table 62 : Trends in Per Capita Real Gross Domestic Product Growth, by Region, 2016-2019
- Table 63 : List of Acronyms Used in the Market for mRNA Therapeutics
- List of Figures
- Summary Figure : Global Market for mRNA Therapeutics, by Country/Region, 2020-2026
- Figure 1 : Global Prevalence of Breast Cancer Cases, by Region/Country, 2015-2025
- Figure 2 : Global Epidemiology of Colorectal Cancer, by Region, 2000-2030
- Figure 3 : Global Cancer Related Deaths, by Cancer Type, 2000-2030
- Figure 4 : Share of Global Cancer-Related Deaths, by Cancer Type, 2015
- Figure 5 : Case Fatality Rate Share, Global Viral Outbreaks, 2020
- Figure 6 : Global Incidence Share of Hypertension, by Patient Group Type, 2020
- Figure 7 : Global Prevalence of Angina Pectoris and Stroke (Survivors), 2004-2030
- Figure 8 : Global Prevalence of Congestive Heart Failure and Stroke, 2004-2030
- Figure 9 : Trends in Obesity Composition of the Global Population, 2012-2025
- Figure 10 : Obesity and Severe Obesity vs. General Population in the U.S., 2018 and 2025
- Figure 11 : Global Share of Diabetes, by Type
- Figure 12 : Global Prevalence of Diabetes, by Type, 2018 and 2040
- Figure 13 : Global Symptomatic Prevalence of Key Musculoskeletal Disorders, 2012-2025
- Figure 14 : Global Deaths, by Musculoskeletal Disorder, 2000-2030
- Figure 15 : Global Deaths from Digestive Diseases, by Region, 2015-2025
- Figure 16 : Global Mortality Share, by Chronic Disease Type, 2019
- Figure 17 : Global Shares of DALYs, by Chronic Disease Type, 2019
- Figure 18 : Estimated World Population and Annual Growth, by Age Group, 2000-2030
- Figure 19 : Total Global Population, by Select Country/Region, 2000-2030
- Figure 20 : U.S. Population Estimates and Projections, by Age Group, 2000-2030
- Figure 21 : Estimates of Anticipated U.S. Life Expectancy at Birth, by Gender, 2005-2020
- Figure 22 : European Population Estimates and Projections, by Age Group, 2000-2030
- Figure 23 : Japanese Population Estimates and Projections, by Age Group, 2000-2030
- Figure 24 : Global Market for mRNA Therapeutics, by Country/Region, 2020-2026
- Figure 25 : Global Market for mRNA Therapeutics, by Product Segment, 2020-2026
- Figure 26 : Global Market Shares of mRNA Drugs and Therapies, by Product Type, 2026
- Figure 27 : Global Market for mRNA Therapeutics, by Disease Type, 2020-2026
- Figure 28 : Global Market Shares of mRNA Therapeutics, by Leading Company, 2021
- Figure 29 : Trends in Per Capita Real Gross Domestic Product Growth, by Region, 2016-2019
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook